Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that George Ng, Chief Executive Officer, will present a corporate update at the MedInvest Biotech and Pharma Investor Conference. David Young, Processa’s President of Research & Development, will participate virtually.